955-96-4

Usage

Uses

Used in Pharmaceutical Research and Development:
4-AMINO-N-(4-METHYLPHENYL)BENZAMIDE is used as a reagent or building block for the synthesis of various pharmaceuticals and organic compounds. Its structural properties and functional groups make it a promising candidate for the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
4-AMINO-N-(4-METHYLPHENYL)BENZAMIDE is used in the field of medicinal chemistry for its potential applications in drug discovery and design. Its unique structure and functional groups allow for the exploration of its interactions with biological targets and the development of new therapeutic agents.
Used in Biological Research:
4-AMINO-N-(4-METHYLPHENYL)BENZAMIDE is being investigated for its potential biological activities and pharmacological effects. Its amine and benzamide groups may contribute to its interactions with biological systems, making it a valuable tool for studying various biological processes and mechanisms.
Used in Laboratory Settings:
4-AMINO-N-(4-METHYLPHENYL)BENZAMIDE is commonly used in research and laboratory settings for its versatility as a reagent or building block in the synthesis of various compounds. Its presence in these settings allows for the exploration of its potential applications and the development of new methodologies and techniques in chemical research.

InChI:InChI=1/C14H14N2O/c1-10-2-8-13(9-3-10)16-14(17)11-4-6-12(15)7-5-11/h2-9H,15H2,1H3,(H,16,17)

Upstream product

• 1079387-49-7 4-((dimethylamino)methyleneamino)-N-4-tolyl-benzamide 
• 624-31-7 4-tolyl iodide 
• 2835-68-9 4-aminobenzamide 
• 150-13-0 4-amino-benzoic acid 
• 106-49-0 p-toluidine 
• 122-04-3 4-nitro-benzoyl chloride 
• 6917-08-4 N-(4-methylphenyl)-4-nitrobenzamide 

Downstream Products

• 90233-93-5 C₁₆H₁₉N₃O₃S 

Relevant academic research and scientific papers

Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors are the first and most successful drugs designed to exploit the concept of synthetic lethality (SL) between PARP-1 and BRCA1/2, which provides a novel strategy for tumor treatment. However, narrowed indications and resistance to PARP-1 inhibitors have hampered their further clinical application. Inducing “BRCAness” by targeting other targets, which will directly or indirectly disturb the homologous recombination (HR) repair pathway of double-strand DNA breaks (DSBs), is a promising strategy for expanding the clinical application of PARP-1 inhibitors and overcoming resistance to these inhibitors. Tankyrase1/2 (TNKS1/2) are involved in the nonhomologous end-joining (NHEJ) DNA repair pathway by regulating Wnt/β-catenin signaling. TNKS1/2 can also induce a “BRCAness” phenotype by regulating Wnt signaling, which increases the sensitivity of tumor cells with BRCA proficiency to PARP-1 inhibitors. These results suggest that cotargeting PARP1/2 and TNKS1/2 not only exerts a synergistic effect in the treatment of tumors but also provides a novel strategy for expanding the clinical application of PARP-1 inhibitors and overcoming resistance to PARP-1 inhibitors. Therefore, a series of dual PARP-1/2 and TNKS1/2 inhibitors were rationally designed, synthesized, and evaluated for their pharmacological properties. Among these candidates, compound I-9 showed excellent inhibitory activity as it inhibited PARP-1/2 and TNKS1/2 with IC50 values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM, respectively. I-9 exhibited favorable synergistic antitumor efficacy in both BRCA-mutant and BRCA-wild-type cancer lines. Moreover, I-9 exerted prominent dose-dependent antitumor activity in an HCT116 cell-derived xenograft model and was significantly more efficacious than olaparib and E7449. Overall, the present study indicated that I-9, a dual PARP-1/2 and TNKS1/2 inhibitor, is a novel and promising agent for cancer therapy.

Amidation of aryl halides catalyzed by the efficient and recyclable Cu 2O nanoparticles

Cu2O nanoparticles/DMEDA (N,N′-dimethylethylenediamine) was proved to be an efficient catalyst system for amidation of aryl halides under mild condition. This method displayed excellent selectivity and the catalyst was recyclable without loss of activity. The low cost, simple operation and excellent yields make this approach attractive for industrial applications. Cu2O nanoparticles/DMEDA (N,N′-dimethylethylenediamine) was proved to be an efficient catalyst system for amidation of aryl halides under mild condition. This method displayed excellent selectivity and the catalyst was recyclable without loss of activity. The low cost, simple operation and excellent yields make this approach attractive for industrial applications. Copyright

The use of formamidine protection for the derivatization of aminobenzoic acids

(Chemical Equation Presented) N,N-Dimethylformamidine and novel N,N-diisopropylformamidine protecting groups were used to carry out a one-pot conversion of aminobenzoic acids into the corresponding amides. General conditions for an in situ transformation of aminobenzoic acids and their heterocyclic analogues into the corresponding formamidine-protected acid chlorides were developed. These chlorides were used in reactions with amines, including poorly reactive anilines. The protected amides were then smoothly deprotected by heating with ethylenediamine derivatives, resulting in a general procedure for the one-pot transformation of aminobenzoic acids into their amides. Our one-pot procedure was successfully applied to the preparation of several compounds of pharmaceutical interest.

Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor

Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities. Here, we report that N-(5-amino-2-pyridinyl)-4-(trifluoromethyl)benzamide (18f, TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1 IC 50 = 0.80 ± 0.05 μM, COX-2 IC50 = 210 ± 10 μM). This compound causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. Our results show that COX-1-selective inhibitors can be analgesic agents without causing gastric damage.

Synthesis and Antiviral Activity of Sulfonamidobenzophenone Oximes and Sulfonamidobenzamides

To find antiviral agents, various sulfonamidobenzophenone oximes (II) were synthesized from the appropriate m-sulfonamidobenzophenones by hydroxylamine reaction.The reaction products were generally obtained as syn/anti mixtures which were separable by fractional crystallization.The anti isomer had more potent antipoliovirus activity than the syn isomer.Various sulfonamidobenzamides (III) which were structurally related to II were synthesized by the reaction of amino-substituted benzamides with sulfuryl chloride or amines with (aminosulfonyl)benzoyl chloride.Antiviral activity was examined by the plaque-inhibition test.Compounds 5, 36, and 69 exhibited strong antipicornavirus activity.The structure-activity relationships are discussed.